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Mice (Balb/c), with peanut allergy induced, were subjected to desensitization therapy with the use of pea protein 
extract (PE) or isolated globulin fractions: legumin (PL) and vicilin (PV). B- and T-cell responses to peanut proteins 
were analysed by determination of the IgE, IgG1, and IgG2a antibody levels in plasma and the concentration of IL-
4, IFN-gamma and IL-10 cytokines secreted by isolated splenocytes. 
Conducted studies have demonstrated that immunotherapy with proteins resulted in the decrease of total IgE 
and peanut-specific IgG1 levels and significantly enhanced synthesis of peanut-specific IgG2a in plasma (ELISA 
method) and at the cellular level (ELISPOT type B). A successful and effective immunotherapy is related to the shift 
in profile of lymphocytes from Th2 subpopulation towards Th1 subpopulation. In our studies significant increase in 
the activity of Th1 lymphocytes was observed in groups desensitized with pea protein extracts (PE) and pea legumin 
fraction (PL). In these groups, significant statistic decrease in IL-4 secreted and increase in IL-10 level were found.
Desensitization method with the use of pea proteins being suggested in the presented studies can be an 
alternative method for specific immunotherapy for people, especially with strong allergic reaction to peanuts; 
however, this method needs further studies with mouse model. 
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Peanut allergy is one of the most serious disorders among the immediate hypersensitivity 
reactions and it appears to be a growing problem. The most common treatment of food allergy 
is exclusion of the component causing hypersensitivity from diet. However, in case of allergy 
to peanuts, this method is not suitable due to the possible occurrence of peanuts in foods, 
cosmetics and pharmaceutical products. Another problem is that traces of peanut allergens 
are sufficient to induce strong reaction (HouriHAne et al., 1997; BlumcHen et al., 2010). 
Mechanism of peanuts allergy is the subject of extended studies; however, there are still more 
questions than answers related to this aspect. Recent studies have proven that extracts from 
peanuts and nuts, contrary to milk or eggs, were able to activate complement system both in 
mice and people, which increased their ability to induce anaphylaxis (kHodoun et al., 2009). 
However, lack of definitive explanation of the mechanism of food hypersensitivity to peanuts 
limits therapeutic applications (THyAgArAjAn et al., 2010). Recently, a lot of attention has 
been focused on novel specific immunomodulatory therapies for food allergy, including oral 
immunotherapy (OIT) and sublingual immunotherapy (SLIT) (BlumcHen et al., 2010; Frew, 
2010). Allergen-specific immunotherapy (ASIT) has been reported to modify different 
aspects of the immune system, inducing shift of allergy-promoting Th2 cells to Th1 cells, 
epitope-specific T-cell anergy, and allergen-specific regulatory T cells that suppress the 
responses of effector T cells (ArpS et al., 1998; uermöSi et al., 2010). 
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In the case of food allergies (especially concerning the peanut allergy), the oral 
administration of allergic proteins appears to be disapproved by the medical staff. Mortal 
incidence due to incorrect peanut protein administration with subcutaneous injection was 
reported and thus the clinical experiment ceased (oppenHeimer et al., 1992). Recently the 
reports on the possibility of oral (BlumcHen et al., 2010) or sublingual administration of 
peanut proteins (kim et al., 2011) have been published, however, the results of the experiment 
have not been confirmed and the effect of treatment appears to be dependent on a number of 
factors (THyAgArAjAn et al., 2010). The possibility of strong hypersensitivity reaction to 
peanut protein administered is significantly important. In such situations, it is recommended 
to use recombinant antigens or proteins that are characterized by a high degree of 
immunological similarity to allergens, resulting from considerable amino acids homology, 
but not having such high allergenic potential. Studies performed by ponS and co-workers 
(2004) on animal model confirmed effectiveness of specific immunotherapy with soybean 
proteins in mice sensitized to peanuts. However, soybean also has strong allergenic properties 
that can be a risk, to some extent, during the therapy (SAvAge et al., 2010). Additionally, 
a problem may exist for patients sensitised to peanuts that could previously consume soybean 
and already showed an immune response to it. 
In the presented studies, specific immunotherapy was performed with the use of pea 
proteins to down-regulate the peanut-allergic responses in mice. The reason for the use of pea 
proteins is their high similarity with peanut proteins, especially globulin allergens (Ara h1 
and Ara h3). Whereas, allergenicity of pea proteins is relatively low, which guarantee safeness 
of the method and promise that its usage in the future would not threat human life. 
 1. Materials and methods
1.1. Mice and reagents 
Five-week-old female Balb/c mice purchased from Medical Research Centre, PAS, Warsaw, 
Poland, were maintained on legume-free feed. Standard guidelines for the care and use of 
animals were followed. Aluminium hydroxide gel was used as an adjuvant (Sigma A8222). 
1.2. Preparation of proteins
The crude peanut extract (PnE) and the crude pea extract (PE) were prepared from defatted 
raw flour. The proteins (1:10, w/v) were extracted with PBS for 2 h at room temperature. 
After centrifugation at 20 000 g for 60 min., the supernatant was filter-sterilized, frozen, 
and stored at –20 °C until further use. Protein concentrations were determined using the 
Bradford’s method with BSA as a standard. Reducing SDS-PAGE from the extracts showed 
protein bands ranging from 6.5 to approximately 100 kDa (not shown). 
The pea globulins were extracted as previously described (FreiTAS et al., 2000) and then 
fractioned by ammonium sulphate precipitation (mAleki et al., 2000). Isolated pea legumin 
11S (PL) and pea vicilin 7S (PV) were purified by ion-exchange chromatography on the 
column packed with DEAE-Sepharose (Sigma DFF100) and lyophilized for further analyses. 
Purified fractions were eluted from the Biosep-SEC S-2000 column in the HPLC system as 
the single peaks (data not presented). 
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1.3. Mouse treatment protocol 
Peanut sensitization and challenge were preformed according to previously described 
protocol (ponS et al., 2004) with modifications. Sensitization was performed by intraperitoneal 
(IP) administration of 0.5 mg PnE in PBS with aluminium hydroxide (0.3 ml injected) on 
days 1, 7, and 21. Desensitization was started two weeks after last sensitization dose and was 
given IP 3 times per week for 8 weeks. For peanut desensitized group the dose was used 0.5 
mg of PnE; for pea desensitized groups: 1 mg of PE; 0.5 mg of PL and 0.25 mg of PV (a dose 
selected according to the results found in previous experiments). For negative controls, 
sham-desensitized mice received PBS (group PnE/PBS). Naive mice received only PBS 
during sensitization and desensitization (group PBS/PBS). Challenges with PnE (1 mg in 
0.3 ml PBS) were started 2 weeks after the last desensitization dose. One day prior to 
extinguishing, sensitization to peanuts was assessed. The Local Care Use of Animal 
Committee (authorization 11/2007) approved animal handling and experimental procedures. 
1.4. Measurement of serum peanut-specific IgG1, IgG2a, IgE and total IgE levels
Tail vein blood was obtained during sensitization, treatments, and after desensitization. The 
blood was incubated for 1 h at 37 °C and centrifuged at 14 000 g for 10 min. Then, the sera 
were collected and stored at –20 °C. 
The levels of peanut-specific IgG1, IgG2a, and IgE were measured by ELISA as 
previously described (lee et al., 2001) with minor modifications. The plates were coated with 
PnE or PE at 20 μg ml–1 or globulin fractions at 10 μg ml–1. Sera were diluted at 1:50 000, 
1:1000, and 1:5 for determination of IgG1, IgG2a, and IgE, respectively. After incubation for 
2 h at 37 °C, the plates were washed with PBS–T (PBS with 0.05% Tween 20) and biotinylated 
rat anti-mouse IgG1 (550331, Becton Dickinson), IgG2a (553388, Becton Dickinson), or IgE 
(553414, Becton Dickinson) antibodies were added. After washing, streptavidin peroxidase 
conjugate (E2886, Sigma) was added (1 h incubation). The enzymatic reaction was developed 
with TMB (T5525, Sigma) for 15 min. Absorbance was measured at 450 nm using Sunrise-
Tecan automatic reader. 
Total IgE was determined by the ELISA assay according to the manufacturer’s 
instructions (OptEIA™ Mouse IgE Set – 555248, Becton Dickinson). Serum was diluted at 
1:100. 
For each mouse, the immunoglobulin concentrations were the mean of triplicates. 
1.5. Spleen lymphocyte isolation, cytokine analysis 
Lymphocytes from spleen were isolated according to a standard method (Maddaloni et al., 
2006). A total of 2×106 cells per 1 ml were cultured in the complete medium at 37 °C in the 
atmosphere of 5% CO2. Complete cell culture medium containing RPMI 1640 medium 
(R8758, Sigma) was supplemented with 10% heat inactivated newborn calf serum (N4762, 
Sigma), 1% non-essential amino acids (M7145, Sigma), and 1% penicillin-streptomycin 
solution (P4333, Sigma) (cRPMI). Cells were cultured in the medium without stimulation 
factor (negative control) or in the medium stimulated with PnE (100 µg ml–1), peanut globulin 
fractions (50 µg ml–1), or ConA (5µg ml–1) (positive control). 
Levels of IFN-gamma, IL-4, and IL-10 in the supernatants of 48-h cultures were 
determined in triplicates using commercial enzyme-linked immunosorbent assay (ELISA) kit 
reagents according to the manufacturer’s instructions (BD Pharmingen, Mississauga, Canada: 
Mouse IFN- γ ELISA set - BD 555138, Mouse IL-4 ELISA set - BD 555232, and Mouse IL-
10 ELISA set - BD 555252).
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1.6. B cell Ab ELISPOT 
For antibody-formatting cells (AFC), counting IgG antigen-specific ELISPOT analyses were 
performed according to a standard method (mAddAloni et al., 2006). The MultiScreen-IP 
plates (Millipore, MSIPS4510) were coated with 20 μg ml–1 of antigen in sterile PBS 
overnight at 4 ºC. The plates were blocked with cRPMI at 37 ºC for 1 h, and next washed five 
times with PBS. A total of 100 µl of cells from spleen at 1×105 concentrations were added to 
the wells. The plates were incubated overnight at 37 ºC in 5% CO2 atmosphere. To detect 
AFC response, anti-mouse IgG-HRP conjugates (A4416, Sigma) were added, and the plates 
were incubated overnight at 4 ºC. After washing, the reaction was developed with AEC 
substrate set (551951, Becton Dickinson) for 15 min at room temperature and then stopped 
with water. The spots were quantised with stereo zoom microscope (OLYMPUS, SZX 9) on 
the next day.
1.7. Statistical analysis
Data were analysed by one-way ANOVA, and then differences among means were analysed 
using Fisher-Protected Least Significant difference for multiple-comparison procedure. The 
level of significance was set at P<0.05.
2. Results and discussion
Most studies to design new therapeutic methods in case of patients with strong peanut allergy 
have serious risk for the patient’s health and life. Therefore, animal models are used for this 
aim (lee et al., 2001; ponS et al., 2004). To sensitize Balb/c mice, peanut proteins (PnE) were 
administered at 0.5 mg dose to mice. A dose higher than recommended, induced low 
production of IgE (li et al., 2000) and could promote production of IgG2a (ArpS et al., 1998). 
Mice, in which peanut allergy induced an increased level of total IgE and peanut-specific 
IgG1, were subjected to desensitization therapy with the use of pea proteins: pea proteins 
extract – PE (1 mg) and isolated pea globulin fractions: 11S legumin – PL (0.5 mg) and 7S 
vicilin – PV (0.25 mg). Pea proteins were selected since they have low allergenicity and high 
similarity to the amino acid sequences of peanut proteins (FæSTe & nAmork, 2010). 
Basic assumption of allergenic immunotherapy is the induction of peripheral tolerance 
to the injected allergens, which is demonstrated by reduction in the level of specific IgE, 
stimulation of production of blocking antibodies (G class), decrease in the activity of effector 
cells, and switching of cytokine profile of T cells (Frew, 2010). The effect of specific 
immunotherapy in our studies was the decrease in total IgE (Fig. 1) in mice serum, however, 
peanut-specific IgE did not show any significant statistic differences (not shown). The applied 
method of determination of specific-IgE may be the cause. 
The lowest level of total IgE was found in the group desensitized with PnE (Fig. 1). 
Whereas IgE level was lower in group PE, there was no statistically significant difference in 
relation to the control group – placebo IT with PBS. In the group of mice to which PL was 
administered IgE level was lower in relation to the control group (PnE/PBS) and in the group 
PV was comparable to levels found in groups desensitized with peanut proteins. Desensitization 
with both peanut proteins and pea proteins reduced production of PnE-specific IgG1 in 
relation to the control group (Fig. 1). No statistically significant differences were observed 
between individual vaccinations. In the desensitized group with pea proteins (PE) significantly 
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Fig. 1. Antibody levels in the serum of peanut-sensitized mice (PnE) after desensitization with: peanut proteins 
extract 0.5 mg dose (PnE/PnE0.5); pea proteins extract 1 mg dose (PnE/PE1); pea legumin 0.5 mg dose  
(PnE/PL0.5); pea vicilin 0.25 mg dose (PnE/PV0.25); placebo IT with PBS (PnE/PBS); native mice sensitized and 
desensitized with PBS (PBS/PBS). A: total IgE level; B: PnE-specific IgG1 level; C: PnE-specific IgG2a level. 
 ⃰ : statistic differences between tested and control group (PnE/PBS) (P<0.05).
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higher level of peanut-specific IgG2a was found, which suggests the activation of Th1 
lymphocytes. The antibody level of peanut-specific IgG2a in the pea legumin IT group (PL) 
was significantly higher than that in PE desensitized group and it was similar to that found in 
PnE desensitized group. In addition, an ELISPOT type B test was performed to determine the 
ability of production of specific IgG antibodies by lymphocytes isolated from spleen and 
stimulated with peanut proteins (Fig. 2). The highest number of B cells secreting specific 
antibodies was identified in groups desensitized with high doses of PE (1 mg) and PL 
(0.5 mg). 
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Fig. 2. The B-cells ELISPOT for IgG produced by splenocytes stimulated with peanut extract (a-PnE),  
peanut legumin 11S – arachin (a-PnL); and peanut vicilin 7S – conarachin (a-PnV). Pooled spleen cells isolated 
from peanut-sensitized mice (PnE) after desensitization with: peanut proteins extract 0.5 mg dose (PnE/PnE0.5); 
pea proteins extract 1 mg dose (PnE/PE1); pea legumin 0.5 mg dose (PnE/PL0.5); pea vicilin 0.25 mg dose  
(PnE/PV0.25); placebo IT with PBS (PnE/PBS); native mice sensitized and desensitized with PBS (PBS/PBS); 
: a-PnE; : a-PnL; : a-PnV; *: statistic differences between tested and control group (PnE/PBS) (P<0.05).
STrAiT and co-workers (2006) reported that allergenic specific antibodies class G could 
block IgE in vivo at anaphylaxis by antigen cleavage and inhibition of FcγRIIb receptors, but 
effective immunotherapy is related not only with production of blocking class G antibodies 
(especially IgG2a and IgG4). Allergenic immunotherapy induces shift in the cytokine profile 
from Th2 subpopulation (IL-4 and IL-5) towards Th1 subpopulation (IFN-gamma) (uermöSi 
et al., 2010). The most significant role in the development of oral tolerance is played by IL-10 
and TGF-β (rollAnd et al., 2009). In addition, increased induction of allergen-specific 
CD4+T cells, demonstrating expression CD25 and Foxp3 (forhend box protein 3) (Frew, 
2010), plays a function in the development of tolerance to T cells as well. In addition to the 
main function of promoting the Th1-type response, IFN-gamma is also considered an early 
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Fig. 3. Production of interleukins by splenocytes stimulated with peanut proteins extract (PnE).  
Medium was the negative control and medium containing ConA the positive control (data not shown).  
Pooled spleen cells isolated from peanut-sensitized mice (PnE) after desensitization with: peanut proteins extract 
0.5 mg dose (PnE/PnE0.5); pea proteins extract 1 mg dose (PnE/PE1); pea legumin 0.5 mg dose (PnE/PL0.5);  
pea vicilin 0.25 mg dose (PnE/PV0.25); placebo IT with PBS (PnE/PBS); native mice sensitized and desensitized 
with PBS (PBS/PBS). A: INF-gamma level; B: IL-4 level; C: IL-10 level. ⃰ : statistic differences between tested and 
control group (PnE/PBS) (P < 0.05).
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mediator of effector T cells and its immediate production is mostly connected with in vivo 
conditions at the beginning of the occurrence of memory T cells. Therefore, production of 
INF-gamma may be considered as a biomarker confirming the ability of antigens (added into 
culture, thus being mitogen) to activate T cells (AkdiS & AkdiS, 2009). In our studies, IT with 
peanut proteins (PnE) resulted in almost three-fold increase in the INF-gamma secretion in 
comparison to the control groups (Fig. 3). Surprisingly, high activity of T cells was observed 
in case of desensitized-groups with PL (0.5 mg). In these groups, significant decrease in the 
ability of IL-4 secretion and increase in IL-10 level occurred simultaneously. IL-4 cytokine 
is the main regulator of the process in which B cells switch expression of immunoglobulin 
isotopes. At specific conditions, IL-4 can stimulate B cells for expression and secretion of 
IgG1 or IgE, directing mice response towards Th2-type response (allergy). The administration 
of pea legumin (PL) to mice reduced the PnE-specific secretion of IL-4 (Fig. 3) and thus 
lowered total IgE and PnE-specific IgG1 levels (Fig. 1).
The level of IL-10 can suggest increase of Treg cells activity, which plays significant 
role in food tolerance (AkdiS & AkdiS, 2009). It is easy to interpret the role of IL-4, but the 
increased level of IL-10 is ambiguously explained (HSu et al., 1992). Based on our observation, 
suppression of Th2 by IL-10 cytokines can result in the inhibition of allergy in Balb/c mice.
3. Conclusion 
The desensitization method recommended by us with the use of pea proteins (especially 
legumin) can be an alternative to specific immunotherapy for people with strong allergic 
reaction to peanuts; however, this method still requires further studies. Immunotherapy with 
the use of pea proteins contributed to changes in response of B and T cells in mice. We 
believe that its application in humans can, at least, result in partial increase in the sensitivity 
threshold against peanut proteins, which can develop protection after their accidental 
consumption to some extent.
*
The work was financed by the Ministry of Science and Higher Education from the research funds in the years 
2008–2011 as Research Project No: N N312 250734 
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